Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Umlauf

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
International Journal of Molecular Sciences|November 13, 2021
Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector CellsMadhu S Pandey, Chunlei Wang, Scott Umlauf, et al.
Pharmaceutical Statistics|July 9, 2024
Potency Assay Variability Estimation in PracticeHang Li, Tomasz M Witkos, Scott Umlauf, et al.
Bioorganic & Medicinal Chemistry Letters|February 23, 2002
The synthesis and selective IL-2 inhibitory activity of bis piperazine-phenol Mannich adductsBolin Geng, Paul R Fleming, Scott Umlauf, et al.
Vaccine|June 21, 2014
A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of Influenza B globular head vaccinesLangzhou Song, Ge Liu, Scott Umlauf, et al.
Open Forum Infectious Diseases|March 1, 2016
Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion ProteinsLynda Tussey, Cynthia Strout, Matthew Davis, et al.
Plos One|June 21, 2011
Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in miceGe Liu, Bart Tarbet, Langzhou Song, et al.
Vaccine|July 17, 2012
Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune responseDavid N Taylor, John J Treanor, Eric A Sheldon, et al.
Vaccine|December 8, 2007
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellinJames W Huleatt, Valerian Nakaar, Priyanka Desai, et al.
Antibodies (Basel, Switzerland)|November 21, 2023
Atypical Asparagine Deamidation of NW Motif Significantly Attenuates the Biological Activities of an Antibody Drug ConjugateMingyan Cao, G Patrick Hussmann, Yeqing Tao, et al.
Plos One|May 22, 2008
Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needsLangzhou Song, Valerian Nakaar, Uma Kavita, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|November 13, 2021
Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector CellsMadhu S Pandey, Chunlei Wang, Scott Umlauf, et al.
Pharmaceutical Statistics|July 9, 2024
Potency Assay Variability Estimation in PracticeHang Li, Tomasz M Witkos, Scott Umlauf, et al.
Bioorganic & Medicinal Chemistry Letters|February 23, 2002
The synthesis and selective IL-2 inhibitory activity of bis piperazine-phenol Mannich adductsBolin Geng, Paul R Fleming, Scott Umlauf, et al.
Vaccine|June 21, 2014
A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of Influenza B globular head vaccinesLangzhou Song, Ge Liu, Scott Umlauf, et al.
Open Forum Infectious Diseases|March 1, 2016
Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion ProteinsLynda Tussey, Cynthia Strout, Matthew Davis, et al.
Plos One|June 21, 2011
Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in miceGe Liu, Bart Tarbet, Langzhou Song, et al.
Vaccine|July 17, 2012
Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune responseDavid N Taylor, John J Treanor, Eric A Sheldon, et al.
Vaccine|December 8, 2007
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellinJames W Huleatt, Valerian Nakaar, Priyanka Desai, et al.
Antibodies (Basel, Switzerland)|November 21, 2023
Atypical Asparagine Deamidation of NW Motif Significantly Attenuates the Biological Activities of an Antibody Drug ConjugateMingyan Cao, G Patrick Hussmann, Yeqing Tao, et al.
Plos One|May 22, 2008
Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needsLangzhou Song, Valerian Nakaar, Uma Kavita, et al.
Pageof 2